Joule Unlimited, Inc.

Joule Named 2012 Technology Pioneer by World Economic Forum

Joule Named 2012 Technology Pioneer by World Economic Forum

September 1, 2011

Cambridge, Mass. – September 1, 2011 – Joule Unlimited Technologies, Inc. today announced its recognition as a member of the 2012 class of Technology Pioneers, a prestigious group of 25 industry-changing companies selected annually by the World Economic Forum. Joule was chosen from hundreds of nominees, recognized for the potential of its Helioculture™ technology to significantly impact both business and society through sustainable, cost-efficient and high-volume production of renewable fuels and chemicals.

BG Medicine, Inc.

BG Medicine, Inc. to Present at Baird's 2011 Health Care Conference

BG Medicine, Inc. to Present at Baird's 2011 Health Care Conference

September 1, 2011

WALTHAM, Mass., Sept. 1, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it will present at Baird's 2011 Health Care Conference on Thursday, September 8, 2011, at 12:45 p.m. Eastern Time. Pieter Muntendam, MD, President and CEO of the Company, will participate in a corporate presentation that will include highlights of galectin-3 studies recently presented at the European Society of Cardiology (ESC) Congress 2011.

TransMedics, Inc.

Los Angeles Times features TransMedics' Organ Care System

Los Angeles Times features TransMedics' Organ Care System

August 29, 2011

 

In a story titled, "Study tests if a warm heart makes a better transplant," the Los Angeles Times features Transmedics Organ Care System and its heart trial. 

Click below to view the full story: 

http://www.latimes.com/health/la-he-warm-heart-transplants-20110829,0,185265.story

BG Medicine, Inc.

Results of First Epidemiological Study of Galectin-3: Higher Levels Are Associated With an Increased Risk of Mortality

Results of First Epidemiological Study of Galectin-3: Higher Levels Are Associated With an Increased Risk of Mortality

August 30, 2011

Results Presented at European Society of Cardiology (ESC) Congress 2011

BG Medicine, Inc.

Preclinical Studies Support Galectin-3 as a New Drug Target in Heart Failure - Results Presented at European Society of Cardiology (ESC) Congress 2011

Preclinical Studies Support Galectin-3 as a New Drug Target in Heart Failure - Results Presented at European Society of Cardiology (ESC) Congress 2011

August 31, 2011

Helicos BioSciences Corporation

Helicos BioSciences Expands Its License with Arizona Technology Enterprises Covering Next Generation Sequencing; New Patents Continue to Issue

Helicos BioSciences Expands Its License with Arizona Technology Enterprises Covering Next Generation Sequencing; New Patents Continue to Issue

August 30, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Helicos BioSciences Corporation (OTCQB: HLCS.PK) announced today that it has amended its existing license with Arizona Technology Enterprises (AzTE) to include all activities that fall within the scope of, or constitute the practice of, the licensed patents, and gives Helicos full and unencumbered rights to the associated intellectual property.

BG Medicine, Inc.

Study Shows Galectin-3 Predicts Response to Statin Therapy in Chronic Heart Failure - Results Presented at European Society of Cardiology (ESC) Congress 2011

Study Shows Galectin-3 Predicts Response to Statin Therapy in Chronic Heart Failure - Results Presented at European Society of Cardiology (ESC) Congress 2011

August 29, 2011

WALTHAM, Mass., Aug. 29, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that results from a sub-study of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial were presented at the European Society of Cardiology (ESC) Congress 2011, in Paris, France.

Permeon Biologics Inc.

Permeon Biologics Boldly Go Where No MAb's Gone Before

Permeon Biologics Boldly Go Where No MAb's Gone Before

August 19, 2011

 

Excerpt from BioWorld Today

In terms of their specificity, biologics are magic bullets – or perhaps, magic magnets: Unlike bullets, they do not penetrate their target.

"There hasn't previously been an opportunity to address intracellular pathways with biological molecules," Alex Franzusoff told BioWorld Today. Franzusoff is CEO of Cambridge, Mass. based start-up Permeon Biologics, a company that hopes to change all that.

Click below to view the full BioWorld Today story:

T2 Biosystems, Inc.

T2 Biosystems Completes $23 Million Series D Financing

T2 Biosystems Completes $23 Million Series D Financing

August 10, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems® announced today that it has closed a $23 million series D financing. The round was led by new investor Aisling Capital, LLC, which was joined by existing investors Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, Physic Ventures, Partners Healthcare, Arcus Ventures, RA Capital, Camros Capital and WS Investments. In conjunction with the financing, Josh Bilenker, M.D., Principal at Aisling Capital, will join T2 Biosystems’s Board of Directors.

BG Medicine, Inc.

BG Medicine Announces Fiscal 2011 Second Quarter Results

BG Medicine Announces Fiscal 2011 Second Quarter Results

August 11, 2011

WALTHAM, Mass., Aug. 11, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced its consolidated results of operations for the three and six months ended June 30, 2011, and provided a business update. The Company will host a conference call and webcast today, August 11, 2011, beginning at 9:00 am Eastern Time (details follow below).